Skip to main content
Caplight Logo









Eureka Therapeutics

Eureka Therapeutics

Private
Emeryville, CaliforniaHealthcare & Life Scienceshttps://www.eurekatherapeutics.com/

Last Round

Grant

Jun 6, 2023

Total Funding Raised

$136.6M

Company Overview

Eureka Therapeutics is a biotechnology company that develops novel T-cell therapies and antibody-drug discovery technology for the treatment of solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

t-cell therapysolid tumor treatmentcell therapyartemis platformliver cancer therapycar-t therapyt-cell engineeringantibody discoverybiotechphage displayclinical-stage biotechcancer immunotherapytcr mimicdrug developmentnext-gen car-t

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Eureka Therapeutics Comparables

Compare Eureka Therapeutics with similar companies based on industry and business-model similarity.

Eureka Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Crossbow Therapeutics
82%
Oricell Therapeutics
81%
A2 Biotherapeutics
80%

Eureka Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 6, 2023
Series EMar 17, 2020
Series DJan 22, 2018
Series CSep 23, 2014

Key People

Founding team and executive leadership

Vivien Chan

Chief Operating Officer

Executive Team

Eureka Therapeutics Investors

Notable investors and investment history

Eureka Therapeutics investors
InvestorRounds
Acorn Campus VenturesSeries D, Series C
Suma VentureSeries C, Series D
California Institute for Regenerative MedicineGrant
Yuan CapitalSeries D, Series C
Harbinger Venture CapitalSeries C, Series D
金浦产业投资基金管理有限公司Series D
Acorn Pacific VenturesSeries D

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 22, 2025

    Added Iwai Chem, a chemicals/distribution SMB, as a customer.

  • Aug 12, 2025

    William S. Solari III has joined the Board of Directors.

Eureka Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Eureka Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Eureka Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersEmeryville, California
Employee Range48
Year Founded2006
Last FundingJun 6, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?